Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That site is all the way hacked. I doubt the owners have any control over the site as of now.
I would HIGHLY recommend NOT giving them any payment information and I wouldn't even log into the site using a Username and Password that most have across numerous websites.
We can all assume our UID and passwords have been compromised. However, I believe the payments we've sent to the site IN THE PAST are still secured because it was through a 3rd party. Do NOT PUT NEW PAYMENT INTO INTO THE SITE. I also believe IV owes us all some money for being offline for so long.
Also, PVCT is about to rocket to the moon!!!!!
Game over.
The best part is that you're going to miss out.
This actually saves the company money.
PV-10 Trial Updated
This is the Stage 3 patient cohort expansion we've been waiting on.
"The Company will further expand the Phase 1b portion of the PV-10-pembrolizumab combination study to include a cohort of up to 24 patients who have satellite or in-transit disease (Stage IIIB/C/D melanoma). A first expansion cohort currently is enrolling up to 24 patients with advanced melanoma (Stage IV) who are refractory to checkpoint inhibition."
Except for the PR they just put out 2 weeks ago.
http://provectusbio.com/news/press-releases/provectus-pr-20190219-1
...and a week before that.
http://provectusbio.com/news/press-releases/provectus-pr-20190212-1
Alan Ross is a complete fraud. He's lying in order to create doubt. It's beyond obvious.
Rare Pediatric Disease Designation Priority Review Voucher
"The FDA grants RPDD for diseases that primarily affect children from birth to 18 years old, and affect fewer than 200,000 persons in the U.S. This program is intended to encourage development of new drugs and biologics for the prevention and treatment of rare pediatric diseases"
Here are the stats for each of the 4 cancer types that POETIC displayed this year for PV-10 at ASCO:
1. 800 new cases of neuroblastoma each year in the United States
2. Ewing sarcoma = 1 case per 1 million per year in the United States.
3. rhabdomyosarcoma = Approximately 250 new cases are diagnosed in the U.S. each year
4. Each year, about 800 to 900 new cases of osteosarcoma are diagnosed in the United States
Notice that every one of them fits within the requirements to get the FDA designation?
On September 30, 2016, the Advancing Hope Act of 2016 (Public Law No: 114-229) amended Section 529 of the FD&C Act. Among the changes, the term "rare pediatric disease" now means a disease that meets each of the following criteria:
A. The disease is a serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents.
B. The disease is rare disease or conditions, within the meaning of Section 526.
The Act changed the language of Subsection (A) from, "The disease primarily affects individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents." The full text of the Advancing Hope Act is available at: https://www.gpo.gov/fdsys/pkg/BILLS-114s1878enr/pdf/BILLS-114s1878enr.pdf
Effective 90 days after the enactment of the Advancing Hope Act of 2016, the sponsor of a rare pediatric disease product application that intends to request a priority review voucher must submit such request in a cover letter to their NDA/BLA submission.
https://www.fda.gov/forindustry/developingproductsforrarediseasesconditions/rarepediatricdiseasepriorityvoucherprogram/default.htm
SRPT sold their voucher to Gilead for $125M for a pediatric treatment and this analyst thinks they should have received more money.
https://www.bizjournals.com/boston/news/2017/02/21/sarepta-sells-fda-review-voucher-for-125m-but.html
"analyst Joseph Schwartz said that the price tag was lower than his expectation of $200 million. In recent years, such vouchers have fetched anywhere from $67.5 million to $350 million."
PVCT could be starting 4 (possibly more) P1 trials that each could qualify for a PPDD and thus, a voucher for possibly each one.
Within a one month time frame, the FDA granted two PPDD to Cellectar Biosciences for the same drug treating both neuroblastoma and rhabdomyosarcoma; two of the cancers POETIC just presented on behalf of PV-10 and PVCT at ASCO.
If this is the precedent being set by the FDA, things could start moving very quickly in the near future for PVCT.
SEC co-Director of Enforcement Division praises Provectus' new leadership in SEC press release.
In the SEC’s press release on this matter, Steven Peikin, Co-Director of the SEC’s Enforcement Division said, “The SEC’s settlement with Provectus – which does not include any penalty – takes into account the proactive remediation and cooperation by the company’s new leadership. Provectus fired wrongdoers, took other steps to remedy its controls, and provided SEC staff with critical information regarding its former executives’ expense reimbursement abuses.”
The SEC also noted that following the Company’s investigation of Dees’ travel expenses, a Special Committee of Provectus’ Board of Directors with the help of independent counsel and a forensic accounting firm, reviewed executive expenses in general, and subsequently devoted several months to investigate Culpepper’s travel expenses. Provectus voluntarily shared the results and details of these investigations with the SEC, “reducing the time and resources necessary for the Commission staff to conclude their investigation.”
Dominic Rodrigues, Chairman of the Company’s Board of Directors, said, “We are grateful to Commission staff for working with Provectus to conclude the SEC investigation of the Company. We also appreciate that the SEC recognized prompt and specific remedial acts by Provectus as well as the cooperation afforded to Commission staff by the Company during the investigation.”
https://globenewswire.com/news-release/2017/12/12/1253450/0/en/PROVECTUS-Announces-Resolution-of-SEC-Investigation.html
A few repeats? lol I bet you can't. You're a fool and your ignorance is on full display.
BOARD OF DIRECTORS
Ed Pershing, CPA - Chairman of the Board
Mr. Pershing is Chief Executive Officer of Pershing Yoakley & Associates (“PYA”), a top 20 healthcare consulting and top 100 accounting firm in the U.S. PYA, which he co-founded more than 30 years ago, expanded from a three-employee office to more than 270 employees and five affiliate companies serving more than 3,500 clients in 50 states. Mr. Pershing’s healthcare experience and expertise include turnaround/performance improvement initiatives, long-range planning studies, development of numerous hospital and medical office projects, restructuring of healthcare organizations, liaison between boards of directors and management teams to craft corporate visions and strategies, mergers, acquisitions, divestitures, and leasing arrangements. He has served as an expert witness on healthcare industry matters and in several Certificate of Need appeals. Mr. Pershing also has represented healthcare organizations before regulatory agencies such as the Centers for Medicare & Medicaid Services, Internal Revenue Service, and Departments of Mental Health, Insurance, and Medicaid. He graduated from the University of Tennessee with a Bachelor of Science in Accounting, and was one of 18 professionals from the U.S. and Great Britain to participate in the first Ernst & Ernst Accelerated Healthcare Program, a one-year full-time education and work-study program in healthcare industry matters. Mr. Pershing is a Certified Professional Accountant (CPA).
Dominic Rodrigues - Vice Chairman of the Board
Mr. Rodrigues has served in leadership roles at Provectus since 2017, including former Chairman of the Board. He previously served as President of Rhisk Capital, which provided management consulting, corporate development, and portfolio management services, since 2005. Project industries and technologies included aerospace & defense (a technology-focused investment capital pool; an operational role in a related data communications solutions company), biotechnology, financial services (a capital markets-focused technology company), gaming, healthcare, life sciences, nanotechnology (a venture capital fund investment), wealth management (a start-up private wealth office), and restaurants. Since 2013 Mr. Rodrigues has been an Adjunct Professor of Finance at the Lee Business School of the University of Nevada, Las Vegas, where he teaches valuation and CFA exam preparation courses. His business development, corporate development, finance, and leadership experiences at various companies include SAIC Venture Capital Corporation, the multi-billion dollar subsidiary of research and engineering company SAIC, where he was an observer or member of the board of directors of a number of portfolio companies. Mr. Rodrigues currently serves as a member of the audit & finance committee of Three Square Food Bank. He holds business, economics, and engineering degrees from The Wharton School, the London School of Economics, the Massachusetts Institute of Technology, and the University of Toronto. Mr. Rodrigues also is a Chartered Financial Analyst (CFA).
Bruce Horowitz - Board Member
Mr. Horowitz has served in a leadership role at Provectus since 2017. He previously served as the Managing Director of Capital Strategists, LLC, which provides corporate, strategic, and financial consulting services, since September 2006. He also serves as a trusted advisor to family trusts and private individuals, with a focus on financial asset management, real estate management and special situation investments. Earlier in his career Mr. Horowitz was a charter member of the New York Futures Exchange, a Senior Vice President managing principal equity investment accounts, private equity investments and public offerings at Drake Capital Securities, and managed the trading department at Laidlaw Equities. He was also a partner at Stanley Capital, a private equity buyout firm. Mr. Horowitz was the chairman and a member of two general obligation bond fund committees, raising more than $500 million in general revenue bonds for the Beverly Hills Unified School District. Subsequently, he was named the first chairman of both the state of California-mandated Citizens’ Oversight Committee and Facilities Advisory Committee, overseeing expenditure of all BHUSD general obligation bond funds. Mr. Horowitz is a founding member of the Los Angeles Chapter of the Positive Coaching Alliance. He founded and is currently the president of the Beverly Hills Basketball League, a youth basketball program that serves more than 35,000 families. Mr. Horowitz has also served as a member of the board of directors of the American Youth Soccer Organization and Beverly Hills Little League. He holds a Juris Doctor degree from Benjamin N. Cardozo School of Law in New York City and Bachelor of Arts degree from Washington University in St. Louis.
John Lacey, III, M.D. - Board Member
Dr. Lacey is the former Chief Medical Officer and Senior Vice President of University Health System d/b/a University of Tennessee Medical Center (“UTMC”), a 600+ bed academic medical center based in Knoxville since 1999. Dr. Lacey served continuously in this capacity from 1999 until retirement from UTMC in 2016. He also operated an internal medicine practice for 39 years. Dr. Lacey graduated from the University of Tennessee with a Bachelor’s degree in Nuclear Engineering and the University of Tennessee Medical School (Memphis) with a Doctor of Medicine degree. Dr. Lacey helped create Knoxville Area Project Access, a partnership with the Knoxville Academy of Medicine and providers to give primary and specialty health services to the uninsured and medically underserved, and was the inaugural chair of the Governor’s Health and Wellness Task Force, which focused on improving Tennessee’s national health ranking. Dr. Lacey has been recognized by several entities for contributions to population health.
Jan E. Koe - Board Member
Mr. Koe has a 30-year track record of success in consulting, asset management, real estate and public company governance, and has represented major insurance firms, national retailers and Fortune 500 companies. He is President of GoStar, which is the manager of Real Solutions Opportunity Fund 2005-I and Real Solutions Fund Management LLC and Real Solutions Investment LLC. He is also Principal of Method K Partners, Inc., a commercial real estate firm, which he founded in 1988. He has served on the Board of Directors of ONE Bio, Corp. where he was Chair of the Compensation Committee and a member of the Financial Audit Committee. He holds a degree in Business Administration and Psychology from Luther College.
Hey Fred, how's business been lately? You have got to be the biggest fool I've ever seen on any of these board. And your multiple accounts on the other board are too funny!
I think it's time to start exposing you.
Yeah, you've been saying that for over 4 years now. Maybe one day, if you keep posting enough bull****, you might actually get something right! How many more years do you need? lol
Oh how simple you must be. There has been a complete board change since then and there has also been an SEC investigation in which they specifically praised the changes made by the company. The two thieves are long gone and the only con artists left are people like you. Not one single person that works for the company has ever stolen for the company. This is fact as per the SEC.
Fool you once? Someone as simple as you sounds like you're fooled all the time.
Ha! This idiot posted an article from 2014 saying that PVCT is about to go bankrupt! Ha!
Here we are mid way through 2018 and the company still isn't even close to going bankrupt.
It's funny of much people's credibility fades away when reading their articles in hindsight.
Go here. There's sanity and a lot of good conversation
https://www.investorvillage.com/groups.asp?mb=19572
I'm not convinced that there will be either. If this was a pump-n-dump, the volume leading into this would have been much much higher. I think this is accumulation.
And if there is selling (which there's bound to be eventually) it's not going to be a massive selloff. This has been a nice, steady climb with average volume. This doesn't look like manipulation.
The Glass purchase was pretty big in my eyes. The exact day the SEC results came in he made a purchase.
I know it's going to be tough getting through the ratchet shares but at least it will bring in money for the company. If the share price can continue to hold, I think we're going to be in a good position.
By the way, great to have you back!
Great action today!
I think we'll be in the zone for clinical data starting in February. There may be other announcements but I think Dom is going to be very smart in the way he handles the release of news. He fully understands the importance of getting the share price up.
Oh, hey look! It's this dumbass.
Now lets do a simple math problem.
What's .04123 * 100?
Pete sure does love dilution. Has he ever been a part of a deal that hasn't included massive dilution?
With PVCT's latest announcement, I believe there will be a pop in share price as each part of the plan is implemented. We know the date that funding is required to be in place. I think if you can plan your purchases close to those dates you will do well.